

Restructuring Charges Understate This Firm's True Profits

Our latest featured stock has several unusual restructuring charges hidden away in its annual filing. Last week, we analyzed 406 10-Ks and 10-Qs.

Get the best fundamental research

Analyst Jacob McDonough found a large unusual item buried in the footnotes of GlaxoSmithKline's (GSK) 2019 20-F.

On page 186, GSK discloses \$1.4 billion in restructuring charges hidden in GAAP net income. GSK <u>bundles</u> these charges into income statement line items as follows:

- \$863 million in Cost of sales
- \$436 million in Selling, general and administration
- <u>\$150 million</u> in Research and development
- \$1 in million in other operating expenses

In addition to the restructuring charges, GSK disclosed <u>\$453 million</u> in transaction-related expenses. These expenses were partially offset by <u>\$449 million</u> in profit on the sale of intangible assets and <u>\$264 million</u> in profit on the sale of businesses.

In total, we removed \$1.5 billion in net <u>earnings distortion</u> to calculate GSK's 2019 adjusted <u>core earnings</u>₁ of \$7.6 billion, which is much higher than its GAAP net income of \$6.1 billion.


GSK is no stranger to large amounts of earnings distortion. In its 2015 20-F, GSK disclosed over \$16 billion in unusual gains related to restructuring, including a gain of \$14.3 billion from the disposal of businesses and assets which included the sale of its Oncology business to Novartis AG (NVS). This earnings distortion means GAAP net income in 2015 was overstated by \$6.5 billion.

Artificially high GAAP net income in 2015 gives investors a misleading picture of GSK's business over the last five years. GAAP net income has fallen by 16% compounded annually since 2015 but core earnings and economic earnings – which reveal a more complete picture of profitability by including adjustments to both the income statement and the balance sheet – are trending higher. Since 2015, GSK has grown core earnings by 6% compounded annually and economic earnings by 3% compounded annually.

¹ Our Core earnings are a superior measure of profits, as demonstrated in In <u>Core Earnings: New Data & Evidence</u> a paper by professors at Harvard Business School (HBS) & MIT Sloan. The paper empirically shows that our data is superior to IBES "Street Earnings", owned by Blackstone (BX) and Thomson Reuters (TRI), and "Income Before Special Items" from Compustat, owned by S&P Global (SPGI).







GAAP Net Income Understates GSK's Profit Growth

Sources: New Constructs, LLC and company filings.

GSK's understated earnings in 2019 earn the stock our "Beat" <u>Earnings Distortion Score</u> (as featured on <u>CNBC</u> <u>Squawk Box</u>), which means it is likely to beat consensus expectations.

Other Critical Details on GSK Found by Our Robo-Analyst Technology

Balance Sheet: we made \$52.2 billion of adjustments to calculate invested capital with a net decrease of \$8.8 billion. Our largest adjustment was \$12.8 billion related to midyear acquisitions (18% of reported net assets). See all adjustments made to GSK's balance sheet <u>here</u>.

Valuation: we made \$68.0 billion of adjustments with a net effect of decreasing shareholder value by \$50.1 billion. Apart from total debt, the largest adjustment to shareholder value was \$9.1 billion in the fair value of minority interests. This adjustment is 4% of GSK's market value. See all adjustments to GSK's valuation here.

The Power of the Robo-Analyst

We analyze 406 10-K and 10-Q filings last week, from which our <u>Robo-Analyst</u> technology collected 39,443 data points. Our analyst team made 6,509 forensic accounting <u>adjustments</u> with a dollar value of \$1.6 trillion. The adjustments were applied as follows:

- 2,464 income statement adjustments with a total value of \$91.9 billion
- 2,833 balance sheet adjustments with a total value of \$727 billion
- 1,345 valuation adjustments with a total value of \$814 billion

Figure 2: Filing Season Diligence for Week of March 8 - March 15

	Filings Parsed	Data Points Collected	# of Adjustments	Total Value of Adjustments (\$Billions)
Filing Season Week 4	406	39,443	6,642	\$1,634
Filing Season Total	1,810	198,334	34,188	\$16,450

² Harvard Business School features the powerful impact of our research automation technology in the case <u>New Constructs: Disrupting</u> Fundamental Analysis with Robo-Analysts.



Every year in this six-week stretch from mid-February through the end of March, we parse and analyze roughly 2,000 10-Ks to update our models for companies with 12/31 and 1/31 fiscal year ends. This effort is made possible by the combination of expertly trained human analysts with our "Robo-Analyst." Featured by Bloomberg and Harvard Business School in "Disrupting Fundamental Analysis with Robo-Analysts", our research automation technology uses machine learning and natural language processing to automate and improve financial modeling.

No Substitute for Diligence

Our technology enables us to deliver diligence on fundamentals at a previously impossible scale. We believe this research is necessary to uncover the true profitability of a firm and make sound investment decisions. "Core Earnings: New Data and Evidence," a recent paper from professors at Harvard Business School and MIT Sloan, shows how our adjustments create a measure of core earnings that is more predictive of future earnings than comparable metrics from Compustat and IBES.

Only by reading through the footnotes and making adjustments to <u>reverse accounting distortions</u> can investors and advisors alike get beyond the <u>noise</u> and get the truth about earnings and valuation.

This article originally published on March 17, 2020.

Disclosure: David Trainer, Jacob McDonough, Kyle Guske II, and Matt Shuler receive no compensation to write about any specific stock, sector, style, or theme.

Follow us on <u>Twitter</u> (<u>#filingseasonfinds</u>), <u>Facebook</u>, <u>LinkedIn</u>, and <u>StockTwits</u> for real-time alerts on all our research.



Footnotes adjustments matter. We are the ONLY source.

We provide ratings, models, reports & screeners on U.S. 3,000 stocks, 700 ETFs and 7,000 mutual funds.

HBS & MIT Sloan research reveals that:

- Markets are inefficiently assessing earnings because no one reads the footnotes.
- Corporate managers hide gains/losses in footnotes to manage earnings.
- Our technology brings the material footnotes data to market for the first time ever.

Combining human expertise with NLP/ML/AI technologies (featured by Harvard Business School), we shine a light in the dark corners (e.g. footnotes) of hundreds of thousands of financial filings to unearth critical details.

The HBS & MIT Sloan paper, <u>Core Earnings: New Data and Evidence</u>, shows how our superior data drives uniquely comprehensive and independent debt and equity research.

This <u>paper</u> compares our analytics on a mega cap company to other major providers. The Appendix details exactly how we stack up.

Learn more.

Quotes from HBS & MIT Sloan professors on our research:

Get better research:

"...the NC dataset provides a novel opportunity to study the properties of non-operating items disclosed in 10-Ks, and to examine the extent to which the market impounds their implications." – page 20

Pick better stocks:

"Trading strategies that exploit cross-sectional differences in firms' transitory earnings produce abnormal returns of 7-to-10% per year." – Abstract

Avoid losses from using other firms' data:

"...many of the income-statement-relevant quantitative disclosures collected by NC do not appear to be easily identifiable in Compustat..." – page 14

Build better models:

"Core Earnings [calculated using New Constructs' novel dataset] provides predictive power for various measures of one-year-ahead performance...that is incremental to their current-period counterparts." – page 4

Exploit market inefficiencies:

"These results ... suggest that the adjustments made by analysts and Compustat to better capture core earnings are incomplete. Moreover, the non-core items identified by NC produce a measure of core earnings that is incremental to alternative measures of operating performance in predicting an array of future income measures." – page 26

Fulfill fiduciary duties:

"An appropriate measure of accounting performance for purposes of forecasting future performance requires detailed analysis of all quantitative performance disclosures detailed in the annual report, including those reported only in the footnotes and in the MD&A." – page 33-34



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. Copyright New Constructs, LLC 2003 through the present date. All rights reserved.